Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.56 |
| ▸ | NOS3 | P29474 | 4/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037102 | 1.00 | NOS1 (0.56) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL19150099 | 0.79 | NOS1 (0.54) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL20657618 | 0.79 | NOS1 (0.54) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL9198559 | 0.79 | NOS3 (0.48) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL9198554 | 0.79 | NOS3 (0.48) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL26324825 | 0.78 | NOS1 (0.52) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL10710252 | 0.76 | NOS1 (0.50) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL27426991 | 0.74 | KMT2A (0.45) | NOS1NOS3MAPTKMT2AMEN1 | |
| SCHEMBL486925 | 0.74 | NOS1 (0.67) | NOS1NOS3HTR3EHTR3BHTR3A | |
| SCHEMBL165971 | 0.74 | NOS1 (0.67) | NOS1NOS3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018031521-A1 | AUREOBASIDIUM DERIVATIVES AND METHODS OF SYNTHESIS | AUREOGEN BIOSCIENCES, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| EP-1503979-B9 | PROCESS FOR HYDROGENATING UNACTIVATED IMINES USING RUTHENIUM COMPLEXES AS CATALYSTS | ABDUR-RASHID KAMALUDDIN (CA) | 2014-10-29 | — | — | EP | disclosed |
| EP-1503979-B1 | PROCESS FOR HYDROGENATING UNACTIVATED IMINES USING RUTHENIUM COMPLEXES AS CATALYSTS | ABDUR RASHID KAMALUDDIN (CA) | 2011-01-26 | — | — | EP | disclosed |
| EP-1503979-B1 | PROCESS FOR HYDROGENATING UNACTIVATED IMINES USING RUTHENIUM COMPLEXES AS CATALYSTS | ABDUR RASHID KAMALUDDIN (CA) | 2011-01-26 | — | — | EP | disclosed |
| US-7256311-B2 | Process for hydrogenating unactivated imines using ruthenium complexes as catalysts | ABDUR-RASHID KAMALUDDIN | 2007-08-14 | — | — | US | disclosed |
| US-7256311-B2 | Process for hydrogenating unactivated imines using ruthenium complexes as catalysts | ABDUR-RASHID KAMALUDDIN | 2007-08-14 | — | — | US | disclosed |
| US-7256311-B2 | Process for hydrogenating unactivated imines using ruthenium complexes as catalysts | ABDUR-RASHID KAMALUDDIN | 2007-08-14 | — | — | US | disclosed |
| US-20050209487-A1 | Process for hydrogenating unactivated imines using ruthenium complexes as catalysts | ABDUR-RASHID KAMALUDDIN | 2005-09-22 | — | — | US | disclosed |
| EP-1503979-A1 | PROCESS FOR HYDROGENATING UNACTIVATED IMINES USING RUTHENIUM COMPLEXES AS CATALYSTS | Abdur-Rashid, Kamaluddin (CA) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003097571-A1 | PROCESS FOR HYDROGENATING UNACTIVATED IMINES USING RUTHENIUM COMPLEXES AS CATALYSTS | ABDUR-RASHID KAMALUDDIN (CA) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209487-A1 | Process for hydrogenating unactivated imines using ruthenium complexes as catalysts | HRH3, HRH4, HRH2 | NOS1 1239/4885NOS3 947/4885HTR3E 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.